Dublin, Sept. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global enteral feeding formula market is projected to reach USD 8.2 billion by 2027 from USD 5.2 billion in 2022, growing at a CAGR of 9.5% during the forecast period.
Based on product, the standard formula segment holds the largest share during the forecast period
Based on product, the enteral feeding formulas market is segmented into standard (polymeric), peptide-based (elemental/semi-elemental), disease-specific, and other formulas. In 2021 standard formulas held the largest share, followed by disease-specific formulas. Standard formulas are easily available and widely used to fulfill daily requirements. The rising prevalence of target ailments thus plays a greater role in driving demand for standard formulas.
Based on application, the oncology segment holds the highest growth during the forecast period
In 2021, the oncology segment accounted for the largest share of the enteral feeding formula market, followed by gastrointestinal diseases, neurological disorders, diabetes, and other applications. Increasing burden of cancer, the shift from hospitals to ambulatory care settings and the rising adoption of enteral feeding as an efficient alternative to parenteral nutrition among cancer patients are likely to fuel the demand for enteral feeding formulas in oncological applications.
Based on age group, the adult segment holds the largest share during the forecast period
Based on age group, the enteral feeding formula market is segmented into adult patients (18 years and over) and pediatric patients (neonates under 1 month, infants between 1 month and 2 years of age, children between 2 and 12 years, and adolescents between 12 and 16 years). In 2021, there has been a increase in adult patients accounted for a larger market share. This can be attributed to the growing incidence of cancer in adult patients, As most cancer patients suffer from malnutrition, an increase in cancer cases is expected to increase the demand for effective enteral nutrition. Also increase in chronic diseases are resulting in malnutrition and the rapid increase in the geriatric population are positively impacting market.
Based on end user, the long term care facilities holds the higher market share during the forecast period
In 2021, Long term care facilities have a higher CAGR. Patients suffering from chronic diseases and disorders are advised long-term care or home care, depending upon the severity of the disease/disorder. Due to the increasing pressure on hospitals to curtail the soaring healthcare costs and the COVID-19 outbreak, there has been a shift from extended hospital treatment toward treatment at home. Studies reveal that home enteral nutrition (HEN) is significantly cheaper than home parenteral nutrition in the US. Growing awareness of therapeutic nutrition has contributed to the use of enteral nutrition products by patients at home.Thus end user segment registered higher market share.
APAC is expected to grow at the highest growth rate in 2021
During the forecast period, the Asia Pacific is estimated to be the fastest-growing regional market for enteral feeding formula. Several factors, such as the rising geriatric population, increased awareness of and accessibility to advanced healthcare facilities, rising healthcare spending, the growing focus of key market players on emerging APAC countries, and rapid improvements in the health insurance sector are driving the market growth.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Enteral Feeding Formulas Market Overview
4.2 Asia-Pacific: Enteral Feeding Formulas Market, by Type (2022)
4.3 Enteral Feeding Formulas Market: Geographic Growth Opportunities
4.4 Enteral Feeding Formulas Market, by Region, 2020-2027
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Benefits and Cost-Effectiveness of Enteral Over Parenteral Nutrition
5.2.1.2 Rising Preterm Births Fueling Demand for Enteral Feeding Formulas
5.2.1.3 Growing Demand for Enteral Feeding in Home Care
5.2.1.4 Rapid Growth in Geriatric Population and Disease Prevalence
5.2.2 Restraints
5.2.2.1 Complications Associated with Enteral Feeding
5.2.2.2 Lack of Patient Awareness
5.2.3 Opportunities
5.2.3.1 Emergence of New Products and Innovation
5.2.3.2 High Growth Opportunities in Emerging Countries
5.2.4 Challenges
5.2.4.1 Insufficient Reimbursements for Enteral Nutrition
5.2.4.2 Dearth of Skilled Professionals
5.3 Porter's Five Forces Analysis
5.4 Regulatory Scenario
5.4.1 Regulatory Analysis
5.5 Value Chain Analysis
5.6 Supply Chain Analysis
5.7 Ecosystem Market Map
5.8 Pricing Analysis
5.9 Patent Analysis
5.10 Key Conferences and Events in 2022-2023
5.11 Key Stakeholders and Buying Criteria
5.12 Key Buying Criteria for End-users
6 Enteral Feeding Formulas Market, by Stage
6.1 Introduction
6.2 Adults
6.2.1 Increased Prevalence of Chronic Diseases and Neurological Disorders in Adult Patients to Increase Market Share
6.3 Pediatrics
6.3.1 Growing Disease Prevalence in Pediatric Patients Driving Market Growth
7 Enteral Feeding Formulas Market, by Product
7.1 Introduction
7.2 Standard Formulas
7.2.1 Ease of Accessibility and Cost-Effectiveness Will Increase Market Growth
7.3 Disease-Specific Formulas
7.3.1 Diabetic Formulas
7.3.1.1 Increased Incidence of Diabetes Patients Driving Market Growth
7.3.2 Renal Formulas
7.3.2.1 Rise in Patient Population for Chronic Kidney Disease to Contribute to Market Growth
7.3.3 Hepatic Formulas
7.3.3.1 Rise in Obesity and Alcohol Consumption Drive Demand for Hepatic Formulas
7.3.4 Pulmonary Formulas
7.3.4.1 Rising Disease Prevalence to Drive Demand Growth
7.3.5 Other Disease-Specific Formulas
7.4 Peptide-Based Formulas
7.4.1 Benefits of Peptide-Based Formulas Over Other Segments Positively Impacting Market Growth
7.5 Other Formulas
8 Enteral Feeding Formulas Market, by Application
8.1 Introduction
8.2 Oncology
8.2.1 Growing Incidence of Cancer to Increase Market Share
8.3 Gastroenterology
8.3.1 Increasing Incidence of Gastrointestinal Diseases to Drive Adoption of Enteral Feeding Formulas
8.4 Neurology
8.4.1 High Burden of Neurological Disorders to Fuel Demand for Clinical Nutrition Therapies
8.5 Diabetes
8.5.1 Use of Enteral Feeding Systems in Diabetics Helps Prevent Hyperglycemia and Associated Complications
8.6 Other Applications
9 Enteral Feeding Formulas Market, by End-user
9.1 Introduction
9.2 Hospitals
9.2.1 Growing Chronic and Infectious Disease Prevalence Drives Market Growth
9.3 Long-Term Care Facilities
9.3.1 Nursing Homes
9.3.1.1 Need for Nursing Care in Above-65 Age Group to Drive Market Growth
9.3.2 Assisted Living Facilities
9.3.2.1 Growth in Chronic Disease Prevalence to Support Market Growth
9.3.3 Home Care Agencies & Hospices
9.3.3.1 Limitations Associated with Home Care to Hamper Market Growth
10 Enteral Feeding Formulas Market, by Region
11 Competitive Landscape
11.1 Overview
11.2 Key Player Strategies/Right to Win
11.3 Market Share Analysis
11.4 Revenue Share Analysis of Top Market Players
11.5 Company Evaluation Quadrant
11.5.1 Stars
11.5.2 Emerging Leaders
11.5.3 Pervasive Players
11.5.4 Participants
11.6 Competitive Benchmarking
11.6.1 Company Footprint Analysis
11.6.2 Company Product Footprint
11.6.3 Company Regional Footprint
11.6.3.1 Competitive Benchmarking
11.7 Competitive Scenario and Trends
12 Company Profiles
12.1 Key Players
12.1.1 Abbott
12.1.2 Nestle
12.1.3 Danone S.A.
12.1.4 Fresenius Kabi
12.1.5 B. Braun Melsungen Ag
12.1.6 Otsuka Holdings Co., Ltd.
12.1.7 Nutritional Medicinals, LLC
12.1.8 Kate Farms
12.1.9 Medtrition Inc.
12.1.10 Victus, Inc.
12.1.11 Global Health Products, Inc.
12.1.12 Meiji Holdings
12.1.13 Reckitt Benckiser Group
12.2 Other Companies
12.2.1 Hormel Foods Corporation
12.2.2 Dermarite Industries
12.2.3 Medline Industries, Lp
12.2.4 Real Food Blends
12.2.5 Ajinomoto Cambrooke, Inc.
13 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/ianshz
Attachment
